Panacos Pharmaceuticals Inc. Announces Results of Bevirimat Prospective Study, which Confirm Patient Response Predictors
Published: Jun 18, 2008
WATERTOWN, Mass.--(BUSINESS WIRE)--Panacos Pharmaceuticals, Inc. (NASDAQ: PANC) today announced the completion of a Phase 2b prospective study of bevirimat in treatment-experienced and treatment-naïve patients that confirms the recently discovered factors that predict response to bevirimat, its lead HIV maturation inhibitor. With 14 days of bevirimat treatment, patients with the predictors of response had a statistically significant higher mean viral load reduction than patients with polymorphisms (variants) at Gag amino acid positions 369, 370 or 371.